Literature DB >> 10600599

Insertional mutagenesis of AAV2 capsid and the production of recombinant virus.

J E Rabinowitz1, W Xiao, R J Samulski.   

Abstract

The structural genes of adeno-associated virus serotype 2 (AAV2) have been altered by linker insertional mutagenesis in order to define critical components of virion assembly and infectivity. An in-frame restriction site linker was inserted across the capsid coding domain of a recombinant plasmid. After complementation in vivo, recombinant AAV2 viruses were generated and assayed for capsid production, packaging, transduction, heparin agarose binding, and morphology. Three classes of capsid mutants where identified. Class I mutants expressed structural proteins but were defective in virion assembly. Class II mutants generated intact virions that protected the viral genome from DNase, but failed to infect target cells. The majority of these mutants bound the heparin affinity matrix, suggesting that attachment to the AAV primary receptor was not rate limiting. One class II mutant, H2634, assembled virions and bound heparin using only Vp3, indicating that this subunit is responsible for mediating AAV receptor attachment. Finally, class III mutants assembled virions, encapsidated DNA, and infected target cells. Infectivity of these mutants ranged from 5 to 100% of that of the wild-type, demonstrating for the first time the ability to alter capsid proteins without interfering with infectivity. These AAV virions with altered capsid subunits will provide critical templates for manipulating AAV vectors for cell-specific gene delivery in vivo. In summary, the AAV capsid variants described here will facilitate further study of virus assembly, entry, and infection, as well as advance the development of this versatile vector system. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10600599     DOI: 10.1006/viro.1999.0045

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  39 in total

1.  The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy.

Authors:  Qing Xie; Weishu Bu; Smita Bhatia; Joan Hare; Thayumanasamy Somasundaram; Arezki Azzi; Michael S Chapman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-22       Impact factor: 11.205

2.  Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups.

Authors:  Joseph E Rabinowitz; Dawn E Bowles; Susan M Faust; Julie G Ledford; Scott E Cunningham; R Jude Samulski
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 3.  Adeno-associated Virus as a Mammalian DNA Vector.

Authors:  Max Salganik; Matthew L Hirsch; Richard Jude Samulski
Journal:  Microbiol Spectr       Date:  2015-08

4.  Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6.

Authors:  Zhijian Wu; Edward Miller; Mavis Agbandje-McKenna; Richard Jude Samulski
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

5.  Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization.

Authors:  Michael A Lochrie; Gwen P Tatsuno; Brian Christie; Jennifer Wellman McDonnell; Shangzhen Zhou; Richard Surosky; Glenn F Pierce; Peter Colosi
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

Review 6.  Adeno-associated virus vectors: potential applications for cancer gene therapy.

Authors:  Chengwen Li; Dawn E Bowles; Terry van Dyke; Richard Jude Samulski
Journal:  Cancer Gene Ther       Date:  2005-12       Impact factor: 5.987

7.  A viral assembly factor promotes AAV2 capsid formation in the nucleolus.

Authors:  Florian Sonntag; Kristin Schmidt; Jürgen A Kleinschmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

8.  Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity.

Authors:  Joseph E Rabinowitz; Fabienne Rolling; Chengwen Li; Hervè Conrath; Weidong Xiao; Xiao Xiao; R Jude Samulski
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

9.  A NEW RECOMBINANT ADENO-ASSOCIATED VIRUS (AAV)-BASED RANDOM PEPTIDE DISPLAY LIBRARY SYSTEM: INFECTION-DEFECTIVE AAV1.9-3 AS A NOVEL DETARGETED PLATFORM FOR VECTOR EVOLUTION.

Authors:  Kei Adachi; Hiroyuki Nakai
Journal:  Gene Ther Regul       Date:  2010-10

10.  Identification of a heparin-binding motif on adeno-associated virus type 2 capsids.

Authors:  A Kern; K Schmidt; C Leder; O J Müller; C E Wobus; K Bettinger; C W Von der Lieth; J A King; J A Kleinschmidt
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.